International Journal of Radiation Oncology*Biology*Physics
Clinical InvestigationLocal Control and Survival Following Concomitant Chemoradiotherapy in Inoperable Stage I Non-Small-Cell Lung Cancer
Introduction
Surgery is usually considered the treatment of choice for early stage non-small-cell lung cancer (NSCLC). For medically inoperable patients or those who decline surgery, radical radiotherapy (RT) is generally accepted as the standard of care. Results with radiotherapy alone in Stage I and II NSCLC are disappointing with local failure rates varying between 6% to 70% and 2-year overall survival rates between 33% to 72% (1).
To improve these outcomes, different strategies have been explored such as the combined use of chemotherapy and radiotherapy. In Stage III NSCLC, the addition of chemotherapy to radiation therapy increases survival rates compared with RT alone, as a result of improved local control 2, 3. Limited data suggest that concomitant chemoradiotherapy (CRT) might improve survival in Stage I NSCLC. A meta-analysis from the Non-small Cell Lung Cancer Collaborative Group reported a 13% reduction in the risk of death in patients receiving sequential chemotherapy and radiotherapy compared to RT alone (4). This benefit was present regardless of disease stage. A subgroup analysis of an Australian Phase III trial of radiation with or without chemotherapy in inoperable NSCLC has shown an advantage of combined treatment compared to radiation alone for Stage I and II disease 5, 6.
On the basis of this experience, we adopted CRT as the standard of care for patients with medically inoperable Stage I NSCLC provided that the patient is judged fit for chemotherapy. The aim of this study was to review retrospectively disease control and survival in patients with Stage I NSCLC patients who were treated with CRT or RT between 2000 and 2005.
Section snippets
Methods and Materials
Patients planned to be treated with radical radiotherapy for NSCLC between January 2000 and December 2005 were identified in the Peter MacCallum Cancer Centre (Peter Mac) radiotherapy database. This review was restricted to those patients with Union Internationale Contre le Cancer (UICC) clinical Stage I histologically or cytologically proven NSCLC who were treated with or without concomitant chemotherapy. All patients had a complete clinical examination, a computed tomography (CT) of the chest
Results
Results with respect to the four endpoints are presented by treatment group in Table 2. The 2-year OS rate for patients treated with CRT was 57% (95% confidence interval [CI], 41%–72%) and 33% (95% CI, 18%–51%) in patients receiving RT (Fig. 1).
The local PFS at 2 years was 66% (95% CI, 49%–81%) with CRT and 55% (95% CI, 28%–79%) with RT (Fig. 2). One patient in the RT group underwent salvage surgery following local progression. This patient developed both distant progression (5 months) and
Discussion
This study provides useful benchmark information on survival and disease control in patients with inoperable Stage I NSCLC who were staged and treated using contemporary techniques. Despite the use of FDG-PET staging and concomitant chemotherapy, both local and distant progression were important causes of treatment failure. An effect on survival or local control of the addition of chemotherapy to RT could not be demonstrated. This was expected given the limited number of events in each group
References (19)
- et al.
A randomised Phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial
Radiother Oncol
(1999) - et al.
Reasons for the slow implementations of CHART for patients with non-small cell lung cancer in clinical practice
Radiother Oncol
(2001) - et al.
Sequential radio-chemotherapy (RT-CT) versus radiotherapy alone (RT) and concomitant RT-CT versus RT alone in locally advanced non-small cell lung cancer (NSCLC): Two meta-analyses using individual patient data (IPD) from randomised clinical trials (RCTs)
J Thorac Oncol
(2007) - et al.
Has 3-D conformal radiotherapy (3D CRT) improved the local tumour control for Stage I non-small cell lung cancer?
Radiother Oncol
(2002) - et al.
High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy
Int J Radiat Oncol Biol Phys
(2001) - et al.
Comparison of outcomes for patients with medically inoperable Stage I non-small-cell lung cancer treated with two-dimensional vs. three-dimensional radiotherapy
Int J Radiat Oncol Biol Phys
(2006) - et al.
The role of radiotherapy in treatment of stage I non-small cell lung cancer
Lung Cancer
(2003) - et al.
Outcomes of risk-adapted fractionated stereotactic radiotherapy for Stage I non-small-cell lung cancer
Int J Radiat Oncol Biol Phys
(2008) - et al.
Radical radiotherapy for Stage I/II non-small cell lung cancer in patients not sufficiently fit for or declining surgery (medically inoperable)
Cochrane Database Syst Rev
(2001)
Cited by (0)
The abstract for this article was selected for poster viewing at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
Conflict of interest: none.